Alkermes plc. 8K

Alkermes plc reported strong Q2 2026 financial results with reaffirmed 2026 guidance and announced a CEO transition from Richard Pops to Blair Jackson effective August 1, 2026.

Alkermes plc filed a Form 8-K to furnish its second quarter 2026 financial results and updated 2026 guidance, reporting a 27% year-over-year increase in quarterly revenue to $496.0 million, GAAP net income of $0.5 million and Adjusted EBITDA of $139.2 million, driven by strong growth in proprietary product sales including LUMRYZ, LYBALVI, VIVITROL and ARISTADA. The company highlighted balance sheet strength with $691.6 million in cash, cash equivalents and investments as of June 30, 2026, alongside higher operating expenses related to the Avadel acquisition, amortization of acquired intangibles and a $26.4 million increase in contingent consideration tied to a CVR milestone following positive LUMRYZ phase 3 idiopathic hypersomnia data. Alkermes also reaffirmed its 2026 revenue and Adjusted EBITDA guidance ranges while lowering its EBITDA and widening its expected GAAP net loss range, and announced that Chief Operating Officer Blair Jackson will assume the Chief Executive Officer role effective August 1, 2026, with current CEO Richard Pops transitioning to continue as Chairman of the Board.

Filing Facts

CIK

1520262

Ticker

ALKS

Form

8K

Source Type

fda

Accession

0001193125-26-318844

Alert Tier

7